AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 17613964 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 76
Study 15645312 — intervention group
Group type: EXPERIMENTAL
Intervention: Gamma-ray exposure with an assumed neutron RBE of 35
Number of subjects: 0
Study 12118271 — intervention group
Group type: EXPERIMENTAL
Intervention: Hypertonic/hyperoncotic solution
Number of subjects: 0
Study 9094912 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive-processing approach to self-reports of diet
Number of subjects: 0
Study 9094912 — intervention group
Group type: EXPERIMENTAL
Intervention: Free and prompted report interviews conducted within 1.5 hours of lunch or the following morning
Number of subjects: 0
Study 9094912 — intervention group
Group type: EXPERIMENTAL
Intervention: Delphi technique study (future plan)
Number of subjects: 0
Study 8426176 — intervention group
Group type: EXPERIMENTAL
Intervention: Innovative group and intensive case management program
Number of subjects: 54
Study 8426176 — intervention group
Group type: COMPARATOR
Intervention: Usual community mental health center and rehabilitation services
Number of subjects: 54
Study 3305681 — intervention group
Group type: EXPERIMENTAL
Intervention: 15 mg/die methimazole (group A)
Number of subjects: 28
Study 3305681 — intervention group
Group type: EXPERIMENTAL
Intervention: 30 mg/die methimazole (group B)
Number of subjects: 28
Study 31887222 — intervention group
Group type: EXPERIMENTAL
Intervention: Oil-based contrast during HSG
Number of subjects: 400
Study 31887222 — intervention group
Group type: COMPARATOR
Intervention: Water-based contrast during HSG
Number of subjects: 400
Study 30062365 — intervention group
Group type: EXPERIMENTAL
Intervention: Long Live the Elderly program
Number of subjects: 207
Study 30062365 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 207
Study 27733248 — intervention group
Group type: EXPERIMENTAL
Intervention: Lower fat diet (20% energy, 65% carbohydrate)
Number of subjects: 245
Study 27733248 — intervention group
Group type: EXPERIMENTAL
Intervention: Lower carbohydrate diet (45% energy, 35% fat)
Number of subjects: 245
Study 27733248 — intervention group
Group type: EXPERIMENTAL
Intervention: Walnut-rich diet (18% energy, 35% fat, 45% carbohydrate)
Number of subjects: 245
Study 27733248 — intervention group
Group type: COMPARATOR
Intervention: Lower fat diet vs. lower carbohydrate diet (insulin sensitive women)
Number of subjects: 245
Study 27733248 — intervention group
Group type: COMPARATOR
Intervention: Walnut-rich diet vs. lower carbohydrate diet (insulin sensitive women)
Number of subjects: 245
Study 27733248 — intervention group
Group type: COMPARATOR
Intervention: All groups (C-reactive protein and interleukin-6)
Number of subjects: 245
Study 27733248 — intervention group
Group type: COMPARATOR
Intervention: All groups (Sex hormone binding globulin)
Number of subjects: 245
Study 24077342 — intervention group
Group type: EXPERIMENTAL
Intervention: CODEX index
Number of subjects: 983
Study 22565878 — intervention group
Group type: EXPERIMENTAL
Intervention: Rigid External Distractor (RED)
Number of subjects: 8
Study 22565878 — intervention group
Group type: COMPARATOR
Intervention: Intraoral Appliance (IA)
Number of subjects: 8
Study 20171784 — intervention group
Group type: EXPERIMENTAL
Intervention: 120 mg/day oral raloxifene hydrochloride
Number of subjects: 35
Study 20171784 — intervention group
Group type: COMPARATOR
Intervention: 60 mg/day oral raloxifene hydrochloride
Number of subjects: 35
Study 20171784 — intervention group
Group type: COMPARATOR
Intervention: Oral placebo
Number of subjects: 35
Study 17324007 — intervention group
Group type: EXPERIMENTAL
Intervention: Cethromycin (ABT 773, A-195773, Abbott-195773, A-1957730, A-195773-0)
Number of subjects: 0
Study 17324007 — intervention group
Group type: EXPERIMENTAL
Intervention: Cethromycin (ABT 773)
Number of subjects: 0
Study 16133640 — intervention group
Group type: EXPERIMENTAL
Intervention: hPTH (1-34) 400 U/day (n=28)
Number of subjects: 51
Study 16133640 — intervention group
Group type: COMPARATOR
Intervention: Control group (n=23)
Number of subjects: 51
Study 14694042 — intervention group
Group type: EXPERIMENTAL
Intervention: Gabapentin (GPT) 2,400 mg/day
Number of subjects: 133
Study 11068976 — intervention group
Group type: EXPERIMENTAL
Intervention: Extended 14‐session cognitive‐behavioral group treatment (RPSG)
Number of subjects: 291
Study 11068976 — intervention group
Group type: EXPERIMENTAL
Intervention: Brief 2‐session individual treatment using motivational interviewing (IAI)
Number of subjects: 291
Study 11068976 — intervention group
Group type: COMPARATOR
Intervention: 4‐month delayed treatment control (DTC)
Number of subjects: 291
Study 8631163 — intervention group
Group type: EXPERIMENTAL
Intervention: 3000 IU bolus of heparin
Number of subjects: 55
Study 8631163 — intervention group
Group type: EXPERIMENTAL
Intervention: 5000 IU bolus of heparin
Number of subjects: 55
Study 8631163 — intervention group
Group type: EXPERIMENTAL
Intervention: Monitoring of APTT values
Number of subjects: 55
Study 1531927 — intervention group
Group type: EXPERIMENTAL
Intervention: Terbinafine 250 mg/day for 6 weeks
Number of subjects: 120
Study 1531927 — intervention group
Group type: EXPERIMENTAL
Intervention: Terbinafine 250 mg/day for 12 weeks
Number of subjects: 120
Study 1531927 — intervention group
Group type: EXPERIMENTAL
Intervention: Terbinafine 250 mg/day for 24 weeks
Number of subjects: 120
Study 3904398 — intervention group
Group type: EXPERIMENTAL
Intervention: Regimen A (vindesine, cis-platinum, and etoposide)
Number of subjects: 37
Study 3904398 — intervention group
Group type: COMPARATOR
Intervention: Regimen B (vindesine, cis-platinum, and lomustine)
Number of subjects: 37
Study 3315585 — intervention group
Group type: EXPERIMENTAL
Intervention: Intracoronary streptokinase
Number of subjects: 93
Study 3315585 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous anisoylated plasminogen streptokinase activator complex (APSAC)
Number of subjects: 93
Study 31776732 — intervention group
Group type: EXPERIMENTAL
Intervention: Olanzapine
Number of subjects: 0
Study 30807429 — intervention group
Group type: EXPERIMENTAL
Intervention: Colpassist
Number of subjects: 52
Study 30807429 — intervention group
Group type: COMPARATOR
Intervention: EEAS
Number of subjects: 52
Study 28380132 — intervention group
Group type: EXPERIMENTAL
Intervention: Resistance training (n = 32)
Number of subjects: 69
Study 28380132 — intervention group
Group type: EXPERIMENTAL
Intervention: Aerobic training (n = 32)
Number of subjects: 69
Study 25878124 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention involving the use of magnetic resonance imaging (MRI) to analyze blood flow and vascular deposition of circulating nanoparticles (NPs).
Number of subjects: 1
Study 25878124 — intervention group
Group type: EXPERIMENTAL
Intervention: Nanoparticles (NPs) targeted to inflammatory vascular molecules (VCAM‐1, E‐selectin, ICAM‐1).
Number of subjects: 1
Study 24235952 — intervention group
Group type: EXPERIMENTAL
Intervention: 4mg ondansetron (Group O)
Number of subjects: 90
Study 24235952 — intervention group
Group type: EXPERIMENTAL
Intervention: 8mg dexamethasone (Group D)
Number of subjects: 90
Study 24235952 — intervention group
Group type: EXPERIMENTAL
Intervention: 4mg ondansetron + 8mg dexamethasone (Group OD)
Number of subjects: 90
Study 21562990 — intervention group
Group type: EXPERIMENTAL
Intervention: Polypharmacy (using more than four medications)
Number of subjects: 457
Study 21562990 — intervention group
Group type: EXPERIMENTAL
Intervention: No medication review at baseline
Number of subjects: 457
Study 21562990 — intervention group
Group type: EXPERIMENTAL
Intervention: Medication review
Number of subjects: 457
Study 19591338 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.05% cetylpyridinium chloride (CPC) mouthrinse
Number of subjects: 110
Study 19591338 — intervention group
Group type: COMPARATOR
Intervention: Control mouthrinse without CPC
Number of subjects: 110
Study 16849762 — intervention group
Group type: EXPERIMENTAL
Intervention: ondansetron 8 mg bid with dexamethasone 4 mg daily
Number of subjects: 211
Study 16849762 — intervention group
Group type: COMPARATOR
Intervention: ondansetron 8 mg bid with placebo
Number of subjects: 211
Study 15327614 — intervention group
Group type: EXPERIMENTAL
Intervention: Metronidazole (1000 mg oral before abortion followed by 500 mg twice daily)
Number of subjects: 393
Study 15327614 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 393
Study 15327614 — intervention group
Group type: EXPERIMENTAL
Intervention: Metronidazole (among 153 women with Gram stain confirmation for bacterial vaginosis)
Number of subjects: 393
Study 15327614 — intervention group
Group type: COMPARATOR
Intervention: Placebo (among 153 women with Gram stain confirmation for bacterial vaginosis)
Number of subjects: 393
Study 10647523 — intervention group
Group type: EXPERIMENTAL
Intervention: Taped condition
Number of subjects: 25
Study 10647523 — intervention group
Group type: EXPERIMENTAL
Intervention: Untaped condition
Number of subjects: 25
Study 10647523 — intervention group
Group type: COMPARATOR
Intervention: Healthy control subjects
Number of subjects: 25
Study 9317068 — intervention group
Group type: EXPERIMENTAL
Intervention: Lansoprazole 30 mg b.i.d., clarithromycin 500 mg b.i.d., and metronidazole 500 mg b.i.d. (LCM) for 7 days
Number of subjects: 105
Study 9317068 — intervention group
Group type: EXPERIMENTAL
Intervention: Lansoprazole 30 mg b.i.d., clarithromycin 500 mg b.i.d., and bismuth subsalicylate 524 mg b.i.d. (LCB) for 7 days
Number of subjects: 105
Study 8403910 — intervention group
Group type: EXPERIMENTAL
Intervention: RU 486 (25, 100, 400, and 600 mg); single oral doses administered to pregnant women
Number of subjects: 45
Study 8403910 — intervention group
Group type: EXPERIMENTAL
Intervention: RU 486 (25, 100, 400, and 600 mg); single oral doses administered to non-pregnant women
Number of subjects: 45
Study 8403910 — intervention group
Group type: EXPERIMENTAL
Intervention: RU 486 (200 mg); additional dose for 6 non-pregnant women
Number of subjects: 45
Study 8403910 — intervention group
Group type: EXPERIMENTAL
Intervention: RU 42633, RU 42848, RU 42698; metabolites of RU 486
Number of subjects: 45
Study 2427458 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous magnesium sulphate
Number of subjects: 200
Study 2427458 — intervention group
Group type: COMPARATOR
Intervention: Saline placebo
Number of subjects: 200
Study 30354310 — intervention group
Group type: EXPERIMENTAL
Intervention: Electrogram-based AVO (SmartDelay)
Number of subjects: 275
Study 30354310 — intervention group
Group type: COMPARATOR
Intervention: Nominal atrioventricular delay (120 ms)
Number of subjects: 275
Study 27433065 — intervention group
Group type: COMPARATOR
Intervention: Chlorhexidine gel
Number of subjects: 30
Study 27433065 — intervention group
Group type: EXPERIMENTAL
Intervention: Curcumin gel
Number of subjects: 30
Study 24788377 — intervention group
Group type: EXPERIMENTAL
Intervention: Sevoflurane
Number of subjects: 20
Study 24788377 — intervention group
Group type: EXPERIMENTAL
Intervention: Propofol
Number of subjects: 20
Study 21993576 — intervention group
Group type: EXPERIMENTAL
Intervention: Small-wave incision method
Number of subjects: 40
Study 21993576 — intervention group
Group type: COMPARATOR
Intervention: Linear incision method
Number of subjects: 40
Study 20357310 — intervention group
Group type: EXPERIMENTAL
Intervention: Stepped care preventive intervention for depression and anxiety disorders
Number of subjects: 170
Study 20357310 — intervention group
Group type: COMPARATOR
Intervention: Routine primary care
Number of subjects: 170
Study 18510549 — intervention group
Group type: EXPERIMENTAL
Intervention: L-arginine (18 g daily for 6 months)
Number of subjects: 23
Study 18510549 — intervention group
Group type: COMPARATOR
Intervention: Control (18 g dextrose daily for 6 months)
Number of subjects: 23
Study 15820455 — intervention group
Group type: EXPERIMENTAL
Intervention: Open lateral internal sphincterotomy
Number of subjects: 80
Study 15820455 — intervention group
Group type: COMPARATOR
Intervention: Chemical sphincterotomy with 25 U botulinum toxin
Number of subjects: 80
Study 12583502 — intervention group
Group type: EXPERIMENTAL
Intervention: 4-week intensive outpatient program
Number of subjects: 27
Study 12583502 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 27
Study 10357730 — intervention group
Group type: EXPERIMENTAL
Intervention: Physical training for 4 months
Number of subjects: 0
Study 10357730 — intervention group
Group type: COMPARATOR
Intervention: Physical training for 4 months (after 4 months of no training)
Number of subjects: 0
Study 10357730 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher pre-physical training concentrations of fibrinogen, PAI-1, and D-dimer
Number of subjects: 0
Study 8770627 — intervention group
Group type: EXPERIMENTAL
Intervention: Slightly suppressive L-thyroxine doses (50-200 micrograms/day)
Number of subjects: 50
Study 8770627 — intervention group
Group type: COMPARATOR
Intervention: Control group (matched for age, sex, body mass index, menopausal and thyroid disease)
Number of subjects: 50
Study 1963191 — intervention group
Group type: EXPERIMENTAL
Intervention: Active antihypertensive treatment
Number of subjects: 742
Study 1963191 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 742
Study 6117459 — intervention group
Group type: EXPERIMENTAL
Intervention: 5 mg clotiazepam
Number of subjects: 18
Study 6117459 — intervention group
Group type: EXPERIMENTAL
Intervention: 5 mg diazepam
Number of subjects: 18
Study 6117459 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 18
Study 31600034 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral nonsteroidal antiinflammatory therapy
Number of subjects: 449
Study 29198844 — intervention group
Group type: EXPERIMENTAL
Intervention: Facts Up Front
Number of subjects: 161
Study 29198844 — intervention group
Group type: EXPERIMENTAL
Intervention: binary symbol
Number of subjects: 161
Study 29198844 — intervention group
Group type: COMPARATOR
Intervention: no-label control
Number of subjects: 161
Study 26689171 — intervention group
Group type: EXPERIMENTAL
Intervention: Mobile texting aftercare intervention
Number of subjects: 80
Study 26689171 — intervention group
Group type: COMPARATOR
Intervention: Aftercare-as-usual control group
Number of subjects: 80
Study 25299584 — intervention group
Group type: EXPERIMENTAL
Intervention: NPM1 type A mutations
Number of subjects: 349
Study 25299584 — intervention group
Group type: EXPERIMENTAL
Intervention: Rare type NPM1 mutations
Number of subjects: 349
Study 25299584 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 349
Study 22299715 — intervention group
Group type: EXPERIMENTAL
Intervention: Bismuthyl ecabet 400 mg single dose
Number of subjects: 77
Study 22299715 — intervention group
Group type: EXPERIMENTAL
Intervention: Bismuthyl ecabet 800 mg single dose
Number of subjects: 77
Study 22299715 — intervention group
Group type: EXPERIMENTAL
Intervention: Bismuthyl ecabet 1200 mg single dose
Number of subjects: 77
Study 22299715 — intervention group
Group type: EXPERIMENTAL
Intervention: Bismuthyl ecabet 200 mg single dose
Number of subjects: 77
Study 22299715 — intervention group
Group type: EXPERIMENTAL
Intervention: Bismuthyl ecabet 1600 mg single dose
Number of subjects: 77
Study 22299715 — intervention group
Group type: EXPERIMENTAL
Intervention: Bismuthyl ecabet 1200 mg twice daily (multiple dose)
Number of subjects: 77
Study 20218755 — intervention group
Group type: EXPERIMENTAL
Intervention: Recruitment procedures
Number of subjects: 280
Study 20218755 — intervention group
Group type: COMPARATOR
Intervention: Chi-square and t tests
Number of subjects: 280
Study 17489900 — intervention group
Group type: EXPERIMENTAL
Intervention: Presence of ob/gyn direct access laws
Number of subjects: 0
Study 17489900 — intervention group
Group type: EXPERIMENTAL
Intervention: Alternate specifications explored
Number of subjects: 0
Study 15771277 — intervention group
Group type: EXPERIMENTAL
Intervention: PPG probe measurements
Number of subjects: 30
Study 15771277 — intervention group
Group type: EXPERIMENTAL
Intervention: PPG probe measurements for anterior tibial artery
Number of subjects: 30
Study 15771277 — intervention group
Group type: EXPERIMENTAL
Intervention: PPG probe measurements for posterior tibial artery
Number of subjects: 30
Study 15771277 — intervention group
Group type: EXPERIMENTAL
Intervention: PPG probe measurements from dorsalis pedis artery in intensive care patients
Number of subjects: 30
Study 11994358 — intervention group
Group type: EXPERIMENTAL
Intervention: 800 microg ciclesonide in the morning
Number of subjects: 12
Study 11994358 — intervention group
Group type: EXPERIMENTAL
Intervention: 800 microg ciclesonide in the evening
Number of subjects: 12
Study 11994358 — intervention group
Group type: EXPERIMENTAL
Intervention: 400 microg ciclesonide inhaled twice daily
Number of subjects: 12
Study 11994358 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study 9667257 — intervention group
Group type: EXPERIMENTAL
Intervention: Prognostic Index (constructed using ADJCT, DLNs, HEP, LDH, DFI)
Number of subjects: 233
Study 9667257 — intervention group
Group type: EXPERIMENTAL
Intervention: Prognostic Index (validated in another cohort of 315 patients)
Number of subjects: 233
Study 7859696 — intervention group
Group type: EXPERIMENTAL
Intervention: Hologic DXA
Number of subjects: 11
Study 7859696 — intervention group
Group type: EXPERIMENTAL
Intervention: Lunar DXA
Number of subjects: 11
Study 7859696 — intervention group
Group type: EXPERIMENTAL
Intervention: Norland DXA
Number of subjects: 11
Study 7859696 — intervention group
Group type: COMPARATOR
Intervention: Underwater Weighing (UWW)
Number of subjects: 11
Study 7859696 — intervention group
Group type: COMPARATOR
Intervention: Bioelectric Impedance Analysis (BIA) instruments
Number of subjects: 11
Study 2687193 — intervention group
Group type: EXPERIMENTAL
Intervention: Ioversol
Number of subjects: 80
Study 2687193 — intervention group
Group type: COMPARATOR
Intervention: Sodium/meglumine diatrizoate
Number of subjects: 80
Study 30449328 — intervention group
Group type: EXPERIMENTAL
Intervention: Memantine (10 mg bid)
Number of subjects: 17
Study 30449328 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 17
Study 26994010 — intervention group
Group type: EXPERIMENTAL
Intervention: Splenic irradiation
Number of subjects: 225
Study 26994010 — intervention group
Group type: COMPARATOR
Intervention: No splenic irradiation (Control)
Number of subjects: 225
Study 24782726 — intervention group
Group type: EXPERIMENTAL
Intervention: Sleep group (n=17)
Number of subjects: 35
Study 24782726 — intervention group
Group type: EXPERIMENTAL
Intervention: Sleep group (n=17) with nocturnal waking <60 min
Number of subjects: 35
Study 24782726 — intervention group
Group type: COMPARATOR
Intervention: Wake group (n=18)
Number of subjects: 35
Study 22716774 — intervention group
Group type: EXPERIMENTAL
Intervention: Contingent behavioral incentives (CBI: n = 42)
Number of subjects: 102
Study 22716774 — intervention group
Group type: COMPARATOR
Intervention: Non-contingent behavioral incentives (NCBI: n = 28)
Number of subjects: 102
Study 22716774 — intervention group
Group type: COMPARATOR
Intervention: Treatment as usual (TAU: n = 32)
Number of subjects: 102
Study 20015129 — intervention group
Group type: EXPERIMENTAL
Intervention: DDD pacing
Number of subjects: 30
Study 20015129 — intervention group
Group type: COMPARATOR
Intervention: VVIR pacing
Number of subjects: 30
Study 17639095 — intervention group
Group type: EXPERIMENTAL
Intervention: BNP infusion
Number of subjects: 28
Study 12015790 — intervention group
Group type: EXPERIMENTAL
Intervention: MDI
Number of subjects: 3
Study 12015790 — intervention group
Group type: EXPERIMENTAL
Intervention: MDI+SP
Number of subjects: 3
Study 12015790 — intervention group
Group type: EXPERIMENTAL
Intervention: DPI
Number of subjects: 3
Study 12015790 — intervention group
Group type: COMPARATOR
Intervention: MDI+SP vs. MDI
Number of subjects: 3
Study 12015790 — intervention group
Group type: COMPARATOR
Intervention: DPI vs. MDI
Number of subjects: 3
Study 12015790 — intervention group
Group type: COMPARATOR
Intervention: MDI+SP vs. DPI
Number of subjects: 3
Study 9404175 — intervention group
Group type: EXPERIMENTAL
Intervention: Nalbuphine (0.3 mg.kg‐1)
Number of subjects: 60
Study 9404175 — intervention group
Group type: COMPARATOR
Intervention: Buprenorphine (2.5 micrograms.kg‐1)
Number of subjects: 60
Study 1821970 — intervention group
Group type: EXPERIMENTAL
Intervention: Imipramine
Number of subjects: 23
Study 1821970 — intervention group
Group type: EXPERIMENTAL
Intervention: Amitriptyline
Number of subjects: 23
Study 1821970 — intervention group
Group type: COMPARATOR
Intervention: Imipramine and Amitriptyline
Number of subjects: 23
Study 7032332 — intervention group
Group type: EXPERIMENTAL
Intervention: Perioperative cefamandole
Number of subjects: 39
Study 7032332 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 39
Study 30084152 — intervention group
Group type: EXPERIMENTAL
Intervention: Moisturizing gel containing a pseudo‐ceramide and a eucalyptus extract, applied twice a day for 4 weeks.
Number of subjects: 44
Study 30084152 — intervention group
Group type: COMPARATOR
Intervention: No moisturizer (control group).
Number of subjects: 44
Study 29053121 — intervention group
Group type: EXPERIMENTAL
Intervention: Cavinton R for drop infusions (10 intravenously during 10 days) followed by cavinton R comforte in dose 10 mg, 1 tablet 3 times a day during 90 days
Number of subjects: 164
Study 29053121 — intervention group
Group type: COMPARATOR
Intervention: Basic therapy only
Number of subjects: 164
Study 29053121 — intervention group
Group type: EXPERIMENTAL
Intervention: Cavinton R for drop infusions and cavinton R comforte
Number of subjects: 164
Study 29053121 — intervention group
Group type: EXPERIMENTAL
Intervention: Cavinton R and cavinton R comforte
Number of subjects: 164
Study 25569495 — intervention group
Group type: EXPERIMENTAL
Intervention: Isolite illuminated isolation system
Number of subjects: 50
Study 25569495 — intervention group
Group type: COMPARATOR
Intervention: Saliva ejector
Number of subjects: 50
Study 24508473 — intervention group
Group type: EXPERIMENTAL
Intervention: AZD7009
Number of subjects: 70
Study 24508473 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 70
Study 21958025 — intervention group
Group type: EXPERIMENTAL
Intervention: 2 μg·kg(‐1) fentanyl (group F, n = 40)
Number of subjects: 80
Study 21958025 — intervention group
Group type: COMPARATOR
Intervention: 2 mg·kg(‐1) tramadol (group T, n = 40)
Number of subjects: 80
Study 19280974 — intervention group
Group type: EXPERIMENTAL
Intervention: Finishing Gloss
Number of subjects: 378
Study 19280974 — intervention group
Group type: EXPERIMENTAL
Intervention: Protect‐It
Number of subjects: 378
Study 19280974 — intervention group
Group type: EXPERIMENTAL
Intervention: LC Varnish
Number of subjects: 378
Study 19280974 — intervention group
Group type: EXPERIMENTAL
Intervention: Adper Single Bond
Number of subjects: 378
Study 19280974 — intervention group
Group type: EXPERIMENTAL
Intervention: Nail Varnish
Number of subjects: 378